Bellerophon Therapeutics, a clinical-stage company focusing on cardiopulmonary disease treatments, is advancing its proprietary INOpulse platform for the treatment of pulmonary hypertension. Currently in Phase 3 clinical trial for pulmonary hypertension associated with fibrotic interstitial lung disease and having completed Phase 2 trials for pulmonary hypertension associated with chronic obstructive pulmonary disease and sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness, INOpulse is showing promise as a potentially effective treatment. Originally known as Ikaria Development LLC, Bellerophon Therapeutics changed its name in 2014 and was founded in 2009.